Related Experiment Videos

Selective toxicity of deoxyadenosine analogues in human melanoma cell lines

Biochemical Pharmacology
|November 15, 1986
PubMed

Insights

Researchers tested deoxyadenosine analogues for toxicity against melanoma cells. 2-Bromodeoxyadenosine (BrdAdo) showed significant selectivity and toxicity by inhibiting DNA synthesis and causing fragmentation in sensitive cells.

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Deoxyadenosine analogues are investigated for potential anticancer properties.
  • Melanoma cell lines exhibit varying sensitivities to nucleoside analogues.

Purpose of the Study:

  • To evaluate the in vitro toxicity and selectivity of 19 deoxyadenosine analogues against human melanoma cell lines.
  • To elucidate the mechanism of action for the most promising compounds, particularly 2-Bromodeoxyadenosine (BrdAdo).

Main Methods:

  • In vitro cytotoxicity assays using a panel of human melanoma cell lines.
  • Flow cytometry to analyze cell cycle effects.
  • Assessment of DNA and RNA synthesis inhibition.
  • DNA fragmentation analysis.

Main Results:

  • Several 8-aza derivatives, including 2-fluoro-, 2-chloro-, 2-bromo-, and 2-amino-8-aza-deoxyadenosine, demonstrated potent toxicity and selectivity against deoxyadenosine-sensitive melanoma cells.
  • 2-Bromodeoxyadenosine (BrdAdo) exhibited the greatest selectivity, requiring over 24 hours of exposure to induce toxicity.
  • BrdAdo inhibited DNA synthesis, arrested cells in G1 and S phases, and led to DNA fragmentation in sensitive cell lines, while RNA synthesis was less affected.

Conclusions:

  • The toxicity of BrdAdo is linked to sustained inhibition of DNA synthesis and subsequent DNA fragmentation.
  • BrdAdo demonstrates potential as a selective agent against deoxyadenosine-sensitive melanoma cells, warranting further investigation.

Related Concept Videos